Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Last trade$0.6358
Day change+$0.0373 (+6.23%)
Day range$0.573 – $0.666
Volume69,151
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.96M
Price / earnings
—
Price / book
0.76×
Price / sales
39.9×
EV / sales
-25.15×
EV / EBITDA
0.19×
Profitability
Earnings per share
-$1.93
Return on assets
-143.14%
Return on equity
-243.17%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.36×
Quick ratio
2.05×
Cash ratio
1.77×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DRMA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$74.14K
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$34.01K
$0
$0
$0
$0
$0
$0
$0
Gross profit
$40.13K
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.76M
$2.8M
$1.54M
$1.37M
$1.26M
$1.15M
$1.06M
$1.01M
Research and development
$143.29K
$212.56K
$383.72K
$526.62K
$504.39K
$617.84K
$1.28M
$2.19M
Total operating expenses
$2.9M
$3.01M
$1.93M
$1.9M
$1.76M
$1.77M
$2.34M
$3.2M
Operating income
-$2.86M
-$3.01M
-$1.93M
-$1.9M
-$1.76M
-$1.77M
-$2.34M
-$3.2M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.82M
-$2.97M
-$1.85M
-$1.86M
-$1.69M
-$1.7M
-$2.3M
-$3.15M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.82M
-$2.97M
-$1.85M
-$1.86M
-$1.69M
-$1.7M
-$2.3M
-$3.15M
Net income attributable to common shareholders
-$2.82M
-$2.97M
-$1.85M
-$1.86M
-$1.69M
-$1.7M
-$2.3M
-$3.15M
EBITDA
-$2.85M
-$3.01M
-$1.93M
-$1.9M
-$1.76M
-$1.77M
-$2.34M
-$3.2M
Basic earnings per share
-$0.55
-$0.74
-$0.48
-$1.64
-$1.65
-$1.66
-$4.47
-$9.15
Diluted earnings per share
-$0.55
-$0.74
-$0.48
-$1.64
-$1.65
-$1.66
-$4.47
-$9.15
Recent news
Company coverage with links to the original publishers.
The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.
U.S. stock futures traded mixed on Tuesday as the Santa Claus rally resumed after Monday's declines. Major indices showed minimal movement with the S&P 500 and Nasdaq 100 slightly lower in premarket trading. Key movers included Fonar Corp surging 24.49% on a take-private deal announcement, TEN Holdings jumping 16.31% on a private placement, Boeing rising 0.58% following an $8.6 billion Pentagon contract, and Freeport-McMoRan gaining 1.36% as copper prices hit record highs. The Fed is expected to hold rates steady in January with 83.9% probability.
Dermata Therapeutics (NASDAQ: DRMA) stock surged 20.10% on Wednesday following the announcement of a $12.4 million private placement offering. The company will issue 2,022,062 common shares and warrants priced at $2.04 per share, with expected gross proceeds of $4.1 million. If warrants are fully exercised, the company could raise an additional $8.3 million. Net proceeds will fund consumer research, OTC acne kit launch activities, and working capital. The stock is trading near its 52-week low of $1.96.
Enphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure.
The study's primary endpoint was stabilization or improvement in cardiac functional capacity as measured by Peak VO2 in patients treated with AT-001 1500mg twice daily (BID) compared to placebo.
Applied Therapeutics shares dipped 35.6% to $2.4498 on Friday.
Here are some other stocks moving in today's mid-day session.
Gainers
Ainos, Inc.(NASDAQ: AIMD) jumped 112.6% to $3.6805 after falling more than 12% on Thursday.
Revelstone Capital Acquisition Corp. (NASDAQ: RCAC) shares climbed 89.6% to $10.71. Revelstone Capital Acquisition cancelled special meeting to approve business combination with Set Jet, Inc.
Banzai International, Inc. (NASDAQ: BNZI) surged 74% to $2.92. Banzai International signed a non-binding letter of intent to acquire IGLeads, a cutting-edge automated lead generation platform.
Safe and Green Development Corporation (NASDAQ: SGD) shares rose 56.5% to $2.1307. Safe And Green Development recently issued an update on LOI for acquisition of Xene AI Software platform.
NexImmune, Inc. (NASDAQ: NEXI) gained 30% to $7.67
Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose climbed 27.8% to $0.78 after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Polished.com Inc. (NYSE: POL) gained 27.2% to $8.05.
Swvl Holdings Corp. (NASDAQ: SWVL) gained 27.2% to $2.90.
PolyPid Ltd. (NASDAQ: PYPD) gained 25% to $8.44. PolyPid announced $16.2 million private placement of 3,371,312 shares at $4.81 per share.
AxoGen, Inc. (NASDAQ: AXGN) jumped 20.4% to $8.13 as the company reported ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.